ASML Holding NV (Derivatives) Price | ASML Price Today, Live Chart, USD converter, Market Capitalization
This article provides price information and market statistics for ASML Holding NV (Derivatives), a crypto derivative. It details the current price, all-time high and low, and various fiat currency conversions. The content also includes an overview of the cryptocurrency exchange where ASML is traded and its basic description.
Will Expectations for Another Earnings Beat Recast Align Technology's (ALGN) Digital Dental Growth Narrative?
Align Technology (ALGN) is set to release its Q1 2026 earnings on April 29, with analysts optimistic due to previous revenue growth, earnings beats, and strategic focus on digital dental solutions. While the company's long-term investment narrative hinges on the adoption of clear aligners and digital workflows, competitive pricing and potential margin pressure remain short-term risks. Investors are watching for signs of demand strengthening or softening, particularly in high-value aligner and scanner sales, which will influence perceptions of future earnings beats and the company's financial outlook.
SOLV Technical Analysis & Stock Price Forecast
The technical analysis for Solventum Corp (SOLV) indicates a "Strong Sell" consensus, based on an aggregation of 14 technical signals. Key indicators like MACD and various moving averages suggest a bearish outlook, with the stock trading below its 60-day and 200-day moving averages. The Relative Strength Index (RSI) is neutral, and important support and resistance levels are identified at $62.23 and $67.04, respectively.
Price-Driven Insight from (SOLV) for Rule-Based Strategy
This article provides a price-driven insight for Solventum Corporation (SOLV) for rule-based trading strategies. It highlights a neutral near-term sentiment that could moderate mid-term weakness, with no clear price positioning signal identified and elevated downside risk. The analysis includes institutional trading strategies with specific entry, target, and stop-loss levels for position trading, momentum breakout, and risk hedging, along with a multi-timeframe signal analysis.
Solventum Corp. stock falls Thursday, underperforms market
Solventum Corp. (SOLV) shares dropped 1.21% on Thursday, closing at $63.57. This decline occurred on a mixed trading day, where the S&P 500 Index rose 0.11% and the Dow Jones Industrial Average fell 0.13%. This marks the second consecutive day of losses for Solventum Corp. stock.
Here's why you should hold Solventum stock in your portfolio now
The provided content is empty, so a summary cannot be generated.
Resmed to post quarterly results after market close on April 30
ResMed (NYSE: RMD) announced it will release its third-quarter fiscal year 2026 financial and operational results on Thursday, April 30, 2026, after the New York Stock Exchange closes. Following the release, ResMed management will host a webcast at 1:30 p.m. PT / 4:30 p.m. ET to discuss the results, which will be accessible via its investor relations website, with replays also available. The announcement emphasizes the company's consistent practice of providing transparency regarding its financial disclosures.
Solventum Corp. stock falls Wednesday, underperforms market
Solventum Corp. (SOLV) saw its stock price fall by 1.45% on Wednesday, closing at $64.35. This decline occurred on a generally positive day for the broader market, with the S&P 500 Index and Dow Jones Industrial Average both posting gains. The stock's drop ended a two-day winning streak.
SOLV SEC Filings - Solventum Corporation 10-K, 10-Q, 8-K Forms
This page provides a comprehensive resource for investors to access Solventum Corporation's SEC filings, including 10-K, 10-Q, 8-K forms, and insider trading reports. It highlights various material events reported by Solventum, such as debt reduction strategies, asset sales, governance changes, and details related to 3M Company's ownership and share resales of SOLV stock. The platform offers AI-powered summaries and sentiment analysis for each filing to help users understand key financial and operational disclosures.
Advanced Carbon Materials Market Is Going to Boom |• Hexcel Corporation • Toray Industries Inc
Worldwide Market Reports has published a research study on the Advanced Carbon Materials Market, forecasting its growth from 2026 to 2033. The report, based on primary and secondary research, details market drivers, challenges, opportunities, and competitive landscape, including key players like Hexcel Corporation and Toray Industries Inc. It also provides regional analysis and market segmentation by types and applications to aid strategic decision-making.
Solventum (SOLV) director converts 1,980 RSUs into common stock, holding 5,544 shares
Solventum Corp director Shirley Ann Edwards converted 1,980 vested Restricted Stock Units (RSUs) into common stock on March 27, 2026. This transaction, classified as a derivative exercise rather than an open-market trade, increased her direct holdings to 5,544 shares of Solventum common stock. The RSUs were fully vested and converted at an exercise price of $0.00 per share, reflecting equity compensation settlement.
Director at Solventum (NYSE: SOLV) exercises 1,980 RSUs into stock
Solventum (NYSE: SOLV) director Wendell Amy McBride exercised 1,980 fully vested Restricted Stock Units (RSUs) into common stock, with each RSU converting into one share at an exercise price of $0.00. Following this compensation-related transaction, McBride now directly holds 7,019 shares of Solventum common stock. This transaction does not involve an open-market purchase or sale.
Solventum Corp. stock rises Tuesday, outperforms market
Solventum Corp. (SOLV) shares rose 2.92% on Tuesday, closing at $65.30. This performance outpaced the broader market, as the S&P 500 Index and Dow Jones Industrial Average also saw gains of 2.91% and 2.49% respectively. This marks the second consecutive day of gains for Solventum Corp. stock.
Solventum (NYSE: SOLV) director gains 1,980 shares in RSU exercise
Solventum Corp director Susan D. DeVore exercised 1,980 fully vested Restricted Stock Units (RSUs) into common stock at an exercise price of $0.00 per share. This transaction increased her direct holdings to 5,544 shares of Solventum Common Stock. The filing is categorized as a routine derivative exercise/conversion without any open-market buying or selling.
[Form 4] Solventum Corp Insider Trading Activity
Solventum Corp's Chief Accounting Officer, Mary T. Wilcox, engaged in an insider transaction involving the exercise of restricted stock units (RSUs) into common shares. On March 27, 2026, she converted 5,199 RSUs into an equal number of common shares, with a portion withheld for tax obligations. After these transactions, Wilcox directly holds 5,256 common shares.
Solventum (SOLV) director converts 6,336 RSUs into 11,484 common shares
Solventum Corp director Carrie Smith Cox exercised 6,336 fully vested Restricted Stock Units (RSUs) into common shares on March 27, 2026. Following this transaction, she directly holds 11,484 shares of Solventum common stock. This transaction is an exercise of derivative securities and not an open-market purchase or sale.
3M Company Stock: Navigating Post-Spin-Off Transformation and Industrial Resilience for Investors
3M Company is reshaping its portfolio after the 2024 Solventum spin-off, focusing on core industrial, safety, and consumer segments while managing ongoing legal resolutions. The company's diversified model and leadership in niche markets provide stability and growth potential for North American investors, backed by a strong dividend history. Key challenges include environmental litigation and supply chain disruptions, but strategic shifts and innovation position 3M for long-term resilience.
Solventum Corporation $SOLV Shares Acquired by SG Americas Securities LLC
SG Americas Securities LLC significantly increased its stake in Solventum Corporation (NYSE:SOLV) by 92.3% in Q4, acquiring 44,970 additional shares to hold a total of 93,681 shares valued at $7.42 million. Solventum reported strong Q4 earnings, beating estimates with an EPS of $1.57 and $2.0 billion in revenue, and provided FY2026 EPS guidance of $6.40-$6.60. Analyst ratings are mixed, with a consensus "Hold" rating and an average price target of $90.64.
Solventum (SOLV) Rated Buy by Jefferies After Earnings Beat
Jefferies has reiterated a "Buy" rating and a $32 price target for Solventum (SOLV) following the company's full-year earnings report, which slightly exceeded top-line expectations. This comes after CIBC also reaffirmed its "Outperformer" rating with a $37 price target, noting that Solventum's 2026 forecast is cautiously optimistic while suggesting potential mergers and acquisitions to expand its offerings. Solventum, a healthcare spin-off company, is gaining attention from hedge funds and analysts alike for its market position and future prospects.
3M Company Stock: Diversified Industrial Leader Faces Transformation Amid Legal Resolutions and Portfolio Shifts
3M Company is undergoing a significant transformation, marked by portfolio shifts and legal resolutions, as it refocuses on its core industrial strengths. The company, known for its diversified portfolio across safety, health, and consumer markets, recently spun off its Health Care business into Solventum Corporation. This strategic realignment aims to enhance shareholder value and strengthen 3M's competitive edge through continued innovation and adaptation to market trends, particularly for North American investors.
Solventum (SOLV) director converts 1,980 RSUs into 5,544-share holding
Solventum Corp director Carlos Alban converted 1,980 fully vested Restricted Stock Units (RSUs) into 1,980 shares of common stock at an exercise price of $0.00 per unit. Following this transaction, Alban directly holds 5,544 shares of Solventum common stock. This insider activity is classified as a derivative exercise rather than an open-market trade.
Solventum (SOLV) director converts 1,980 RSUs into 5,606 total shares
Solventum Corp director Mily Elizabeth converted 1,980 fully vested Restricted Stock Units (RSUs) into common shares on March 27, 2026, at an exercise price of $0.00 per unit. Following this transaction, she directly holds 5,606 shares of Solventum common stock. This filing indicates the RSUs are now fully settled with no remaining outstanding units from this grant, and no open-market purchases or sales were reported.
Solventum (NYSE: SOLV) director settles 1,980 RSUs, now holds 5,544 shares
Solventum (NYSE: SOLV) director Harris Bernard A Jr exercised 1,980 Restricted Stock Units (RSUs), converting them into 1,980 shares of Common Stock at a stated price of $0.00 per share. Following this transaction, he now directly holds 5,544 shares of Solventum Common Stock. The RSUs were fully vested prior to settlement, indicating they were part of his existing equity compensation.
Solventum (SOLV) director exercises 1,980 RSUs, lifts direct holdings to 5,544 shares
Solventum (SOLV) director Glenn A. Eisenberg exercised 1,980 fully vested Restricted Stock Units (RSUs), converting them into an equivalent number of common shares at no exercise price. This transaction increased his direct holdings in Solventum to 5,544 shares. The event was an exercise of equity awards, not an open-market purchase or sale.
Solventum Corp (SOLV) Trading Down 3.01% on Mar 30
Solventum Corp (SOLV) shares dropped 3.01% on March 30, reaching an intraday low of $62.65 before closing slightly higher at $62.76. This places the stock 28.84% below its 52-week high but 3.39% above its 52-week low. Analysts have an average target price of $86.72, suggesting a potential upside of 38.18%, with an average "Outperform" recommendation from brokerage firms.
Solventum Corp. stock rises Monday, outperforms market
Solventum Corp. (SOLV) shares increased by 1.10% to $63.45 on Monday, outperforming a mixed market session where the Dow Jones Industrial Average rose and the S&P 500 Index fell. The stock closed 28.06% below its 52-week high of $88.20.
10 Recent Spin-off Companies That Hedge Funds Are Piling Into
This article highlights recent spin-off companies that are attracting significant hedge fund investment. Specifically, it focuses on Everus Construction Group Inc. (NYSE: ECG), detailing its recent financial performance and analyst upgrades. The company exceeded earnings and revenue forecasts, reported a record backlog, and received boosted price targets from Freedom Capital Markets and Cantor Fitzgerald due to strong end-market conditions.
3M Company Stock: Diversified Industrial Leader Faces Legal Headwinds and Strategic Shifts in 2026
3M Company, a diversified industrial leader, is navigating ongoing legal challenges related to PFAS chemicals and earplugs while executing a strategy focused on core growth areas and portfolio optimization. The company's resilience is built on its diversified business model across safety, industrial, transportation, electronics, healthcare, and consumer segments, supported by strong brand recognition, an extensive patent portfolio, and a dividend aristocrat status. Despite legal headwinds and competitive pressures, 3M aims to capture secular trends in electrification, renewable energy, and advanced materials through innovation and financial discipline.
ENSG Financials: Revenue Breakdown, Margins & Competitor Comparison
This article provides a financial analysis of Ensign Group Inc (ENSG), detailing its revenue breakdown, profitability margins, and a comparison with competitors. Medicaid is the largest revenue contributor at 38.7%, and the company reports a gross margin of 14.30% and a net margin of 7.02%. ENSG, with a market capitalization of $11.66B, is benchmarked against SOLV and GH, showing lower gross margins compared to its peers.
Is Align Technology (ALGN) Pricing Reflect Its Recovery Story In Clear Aligners And Digital Dentistry
This article analyzes Align Technology's (ALGN) stock valuation using Discounted Cash Flow (DCF) and Price-to-Earnings (P/E) ratios. The DCF model suggests the stock is undervalued by 22.9%, with an intrinsic value of $215.87 per share. However, its P/E ratio of 28.90x is slightly above the industry average, indicating it might be overvalued based on this metric given its Fair Ratio of 26.08x.
3M Company Stock: Diversified Industrial Leader Faces Legal Headwinds and Strategic Shifts in 2026
3M Company continues to be a diversified industrial leader with extensive exposure across safety, healthcare, and consumer markets. Despite its strong industrial base and innovative reputation, the company is navigating significant legal challenges, including ongoing earplugs litigation and environmental liabilities from PFAS exposure. The recent spin-off of its Health Care business into Solventum aims to streamline operations and enhance focus on high-growth industrial and consumer segments, positioning 3M for opportunities in North American manufacturing recovery and infrastructure spending, while demanding careful investor scrutiny due to these strategic shifts and legal headwinds.
THE COOPER Cyclically Adjusted PB Ratio: 2.20 — 50% Below
The Cooper Companies Inc's (COO) Cyclically Adjusted PB Ratio currently stands at 2.26, which is 48% below its 10-year median of 4.37. GuruFocus rates COO with a GF Score of 96/100 and a GF Value of $102.22, indicating it is significantly undervalued despite having two warning signs for investors. The company's Cyclically Adjusted Book per Share for January 2026 was $31.64, and its current share price is $71.43.
ALGN (Align Technology) Net Change in Cash : $51 Mil (TTM As of Dec. 2025)
Align Technology (ALGN) recorded a Net Change in Cash of $51 million for the trailing twelve months (TTM) ended December 2025, and $90 million for the quarter ended December 2025. GuruFocus assesses ALGN with a GF Score of 89/100 and a GF Value of $249.91, indicating it is significantly undervalued compared to its current price of $166.38, despite having six warning signs for investors. The article details the calculation of Net Change in Cash and provides historical data and comparisons for the company.
Vanguard disaggregates holdings; Solventum (SOLV) Schedule 13G/A shows 0% ownership
The Vanguard Group has filed an amended Schedule 13G/A for Solventum Corp (SOLV), reporting 0% beneficial ownership of the common stock. This change reflects an internal realignment effective January 12, 2026, where certain Vanguard subsidiaries will now report their holdings separately, in reliance on SEC Release No. 34-39538. The filing clarifies that this is an administrative reporting adjustment and not an economic stake change or a transaction involving the purchase or sale of shares.
Solventum Corp. stock falls Friday, underperforms market
Solventum Corp. (SOLV) stock dropped 3.01% on Friday, closing at $62.76, amidst a broad market decline where the S&P 500 Index fell 1.67% and the Dow Jones Industrial Average dropped 1.73%. This decrease ended a two-day winning streak for the company's shares.
The Bull Case For Align Technology (ALGN) Could Change Following FTSE All-World Index Removal – Learn Why
Align Technology (ALGN) was recently removed from the FTSE All-World Index, which could impact its passive investment flows and liquidity profile by affecting how large institutional investors gain exposure to the company. While the exclusion doesn't alter Align's near-term drivers like case volumes and pricing pressures, it introduces a technical factor that intersects with these challenges. Investors should consider how this index change might influence the company's longer-term narrative, especially in light of its revenue guidance and pressure on profitability.
This KB Home Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Tuesday
Citizens analyst James McCanless has initiated coverage on KB Home (NYSE: KBH) with a Market Outperform rating and a $77 price target. This article also details three other analyst initiations: Solventum Corp (NYSE: SOLV) with a Sell rating, Smith Douglas Homes Corp (NYSE: SDHC) with a Market Perform rating, and Generate Biomedicines Inc (NASDAQ: GENB) with a Buy rating. The article highlights the differing ratings and price targets these top Wall Street analysts have given to the respective companies.
Adonis raises $40M to accelerate AI in revenue cycle
Adonis, a healthcare revenue cycle management software vendor, has raised an additional $40 million in Series C funding, bringing its total funding to $95 million. This funding, led by Quadrille Capital, will accelerate product innovation, particularly in AI agents, to address challenges like RCM workforce shortages, claim denials, and underpayments. The company's AI-driven platform helps healthcare organizations like Mount Sinai Health System autonomously manage revenue cycle issues, especially as policy changes are expected to increase uninsured patients and administrative burdens.
Solventum (NYSE: SOLV) Chief Accounting Officer plans retirement
Solventum Corporation announced that Chief Accounting Officer Mary Wilcox intends to retire and resign from her position. Her departure is not immediate; she will remain in her role until a successor is found and appointed, ensuring a smooth transition for the company's accounting leadership. This information was disclosed in an 8-K filing on March 20, 2026.
Therapy animals will reach 100,000 patients and care teams in pilot
Pet Partners and the Baxter Foundation (NYSE: BAX) have launched a two-year pilot program to expand therapy animal visits, aiming to reach 100,000 patients and healthcare workers in three key U.S. regions. This initiative seeks to reduce stress and improve resilience by providing resources, training, and volunteer support, building on the proven benefits of human-animal interaction in healthcare settings. The program also includes research to further understand the impact of therapy animals on healthcare professionals and offers engagement opportunities for Baxter employees.
Solventum Corp (SOLV) Shares Down 3.27% on Mar 24
Solventum Corp (SOLV) shares dropped 3.27% on March 24, reaching an intraday low of $63.10 before closing at $63.54. The stock is currently 27.96% below its 52-week high and 4.68% above its 52-week low. Wall Street analysts maintain an "Outperform" status for SOLV, with an average target price of $86.72, implying a 36.48% upside.
3M Company stock faces renewed scrutiny amid industrial slowdown and legal overhang in 2026
3M Company stock is facing renewed scrutiny in 2026 due to persistent challenges including legal settlements, softening industrial demand, and macroeconomic headwinds. The company's core industrial business is experiencing a slowdown, and ongoing litigation, particularly PFAS water contamination and earplug lawsuits, continues to strain its balance sheet. However, the healthcare segment shows resilience, offering a bright spot amid these challenges for US investors monitoring the diversified industrial conglomerate.
Tri Pointe Homes (NYSE:TPH) Advances As Nyse Composite Keeps Builders Strong
Tri Pointe Homes (NYSE:TPH) experienced an advance, benefiting from the overall strength of the homebuilding sector as indicated by the NYSE Composite. The article highlights the crucial role of the homebuilding sector in North American economic activity, driven by housing demand and evolving buyer preferences. It notes that Tri Pointe Homes focuses on residential construction, including single-family homes, and that the stock's recent movement reflects strong trading activity within the sector.
Mary Wilcox to Retire as Solventum Chief Accounting Officer
Mary Wilcox has informed Solventum of her intention to retire and resign as Chief Accounting Officer. Her departure will be effective following the appointment of her successor. This information is based on an SEC filing from March 24, 2026.
(SOLV) Price Dynamics and Execution-Aware Positioning
This article from Stock Traders Daily provides an AI-driven analysis of Solventum Corporation (NASDAQ: SOLV), highlighting weak near and mid-term sentiment and a neutral long-term outlook. It details specific trading strategies—Position, Momentum Breakout, and Risk Hedging—with entry zones, targets, and stop losses. The analysis also includes multi-timeframe signal data, supporting the bearish near-term outlook for the stock.
Rothschild Redburn initiates Solventum stock with Sell rating
Rothschild Redburn initiated coverage on Solventum Corp. (NYSE:SOLV) with a Sell rating and a $60.00 price target, citing concerns about the company's ability to accelerate organic growth due to its focus on mature and competitive markets. The firm views Solventum's mid-term guidance as optimistic, noting a lack of synergies between its divisions, material exposure to price-pressured segments, and execution risks. This bearish outlook contrasts with other analysts who have price targets ranging from $71 to $105, despite Solventum recently reporting decent revenue growth but missing EPS forecasts in Q4 2025.
Is Solventum Corporation Stock Underperforming the Dow?
Solventum Corporation (SOLV), a healthcare company spun off from 3M in 2024, has been significantly underperforming the Dow Jones Industrial Average. The company's stock has declined nearly 25.4% from its 52-week high, and its recent Q4 fiscal 2025 earnings showed a revenue beat but a significant earnings miss. Despite these struggles, Wall Street analysts maintain a "Moderate Buy" rating with a considerable upside potential of 42.1%.
Solventum Corp. stock falls Friday, underperforms market
Solventum Corp. (SOLV) stock dropped 2.03% on Friday, closing at $65.78, significantly underperforming the broader market as both the S&P 500 and Dow Jones Industrial Average also fell. The stock is now 25.42% below its 52-week high of $88.20, achieved on December 2nd. The market-wide downturn contributed to SOLV's decline during the trading session.
SOLV SEC Filings - Solventum Corporation 10-K, 10-Q, 8-K Forms
This page provides a comprehensive resource for investors and traders to access Solventum Corporation's (SOLV) official regulatory documents, including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms. It features AI-powered summaries of these filings to highlight key information and tracks the company's financial performance, capital structure, and governance in the medical instruments and supplies sector. Recent filings detail insider trading activity, ownership stakes by institutional investors, and a third-quarter 2025 earnings report showcasing debt reduction following a significant divestiture.
3M Company Aktie: Latest Earnings Beat Expectations Amid Industrial Recovery Signals
3M Company exceeded Q4 earnings expectations with adjusted EPS of $2.65 and revenue of $8.1 billion, driven by strong performance in its Safety and Industrial segments. The company's stock surged 4.2% on the NYSE following the positive results, which highlighted its stability as a dividend aristocrat and successful post-spin-off strategic shifts. The report also emphasized 3M's relevance for DACH investors due to its European market presence and consistent dividend payouts.
